ImmunityBio, Inc. IBRX Convertible note receivable
Convertible note receivable at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept ibrx:ConvertibleNoteReceivableNonCurrent.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s convertible note receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s convertible note receivable?
- ImmunityBio, Inc. (IBRX) reported convertible note receivable of $0 in Q1 2026.
- How has ImmunityBio, Inc.'s convertible note receivable changed year-over-year?
- ImmunityBio, Inc.'s convertible note receivable decreased by 100.0% year-over-year, from $7.19M to $0.
- What is the long-term trend for ImmunityBio, Inc.'s convertible note receivable?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s convertible note receivable has grown at a 3.8% compound annual growth rate (CAGR), from $6.13M to $7.38M.
- What does convertible note receivable mean?
- This represents a financial instrument held by the company that grants the right to receive principal and interest, with the option to convert the debt into equity of the issuer. It reflects strategic investments or lending activities outside of standard operations.